Welcome to ClinSync  
(Clinical Trial Oncology Phase I, II)

Mission: To improve success rates in early-stage oncology clinical trials through predictive insights into safety and risk, accelerating the development of effective therapies.

Vision: To enable a future where drug development is guided by predictive intelligence, reducing failure rates and ensuring safer, more effective therapies reach patients faster.

ClinSync is building drug risk intelligence to improve decision-making in clinical trial Phase I, II (Oncology).

Despite advances in science, a large proportion of drugs fails in phase I, II —often due to unanticipated safety risks and adverse drug reactions (ADRs) that emerge too late in the process. These failures cost time, capital, and, most importantly, patient health.

ClinSync addresses this challenge by focusing on risk prediction in Phase I, II  trials.
•	We develop frameworks and data-driven approaches that help:
•	Identify potential safety risks early
•	Reduce uncertainty in clinical decision-making
•	Improve the probability of trial success

Our work sits at the intersection of translational science, clinical insight, and predictive analytics, enabling biopharma companies, clinician-scientists to make more informed, risk-aware decisions.


ClinSync Pte. Ltd.

Org chart

Teams

Offices

ClinSync Pte. Ltd.

Org chart

Teams

Offices

Related companies